Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW J BOULEY

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1831539519
CMS profile
82751
Location
WELLESLEY, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$69,277.46

68 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
EMD Serono, Inc. $29,020.18 35
Genentech USA, Inc. $23,935.52 18
Biogen, Inc. $15,386.46 11
Horizon Therapeutics plc $600.00 2
Novartis Pharmaceuticals Corporation $275.00 1
GENZYME CORPORATION $60.30 1

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW J BOULEY

NPI 1831539519 · CMS profile ID 82751

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

WELLESLEY, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1831539519?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW J BOULEY, NPI 1831539519, CMS profile ID 82751. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831539519?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ANDREW J BOULEY, NPI 1831539519, CMS profile ID 82751. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831539519?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ANDREW J BOULEY, NPI 1831539519, CMS profile ID 82751, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1831539519?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

68 matching records · $69,277.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 68 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–68 of 68.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $204.8704/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950668445 CMS
Genentech USA, Inc. $27.6204/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950668356 CMS
Genentech USA, Inc. $62.4304/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950668387 CMS
Genentech USA, Inc. $69.0004/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950668407 CMS
Genentech USA, Inc. $383.1304/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950668499 CMS
Genentech USA, Inc. $4,200.0004/29/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950668537 CMS
Biogen, Inc. $20.0704/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923394479 CMS
Biogen, Inc. $3,507.0004/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923414435 CMS
Biogen, Inc. $50.0004/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923450525 CMS
EMD Serono, Inc. $4,800.0004/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941505437 CMS
Biogen, Inc. $1,503.0004/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923458695 CMS
EMD Serono, Inc. $45.5503/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941499573 CMS
EMD Serono, Inc. $31.8903/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941499587 CMS
EMD Serono, Inc. $31.9003/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941499599 CMS
EMD Serono, Inc. $68.3303/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941499631 CMS
EMD Serono, Inc. $136.6703/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941499177 CMS
EMD Serono, Inc. $280.0303/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941499191 CMS
Horizon Therapeutics plc $200.0002/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937596911 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17.26 1
PY2020 $13,382.11 11
PY2021 $23,602.57 26
PY2022 $69,277.46 68
PY2023 $49,850.42 62
PY2024 $83,536.29 65
PY2025 $68,274.01 69

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,097.86 1
PY2025 Principal investigator $303,526.14 28
PY2024 Recipient $25,889.20 1
PY2024 Principal investigator $342,854.03 23
PY2023 Principal investigator $245,561.67 9
PY2022 Principal investigator $189,898.75 4
PY2021 Principal investigator $180,393.41 1
PY2020 Principal investigator $21,598.47 22
PY2019 Recipient $979.18 10
PY2019 Principal investigator $16,202.99 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $1,601.16 12/10/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200219
Principal investigator 1 TG Therapeutics, Inc. $1,311.31 12/09/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200225
Principal investigator 1 TG Therapeutics, Inc. $8,000.00 11/30/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200247
Principal investigator 1 Genentech, Inc. $1,038.00 11/20/2025 Non-covered Recipient Entity
DRAGONFLY RESEARCH LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211598248
Principal investigator 1 TG Therapeutics, Inc. $2,002.99 11/01/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200223
Principal investigator 1 TG Therapeutics, Inc. $6,550.00 11/01/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200245
Principal investigator 1 Genentech, Inc. $16,326.00 10/28/2025 Non-covered Recipient Entity
DRAGONFLY RESEARCH LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211598242
Principal investigator 1 Genentech, Inc. $4,166.00 10/28/2025 Non-covered Recipient Entity
DRAGONFLY RESEARCH LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211598245
Principal investigator 1 TG Therapeutics, Inc. $7,075.00 10/01/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200243
Principal investigator 1 TG Therapeutics, Inc. $19,500.00 09/30/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200213
Principal investigator 1 TG Therapeutics, Inc. $300.00 09/30/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200215
Principal investigator 1 Genentech, Inc. $16,138.80 09/23/2025 Non-covered Recipient Entity
DRAGONFLY RESEARCH LLC
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211597715
Principal investigator 1 TG Therapeutics, Inc. $8,525.00 07/31/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200211
Principal investigator 1 Genentech, Inc. $62,162.00 07/21/2025 Non-covered Recipient Entity
DRAGONFLY RESEARCH LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211598225
Recipient Novartis Pharmaceuticals Corporation $3,097.86 07/18/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190292101
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 07/17/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200217
Principal investigator 1 Genentech, Inc. $1,198.00 07/10/2025 Non-covered Recipient Entity
DRAGONFLY RESEARCH LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211598230
Principal investigator 1 Genentech, Inc. $1,584.00 07/04/2025 Non-covered Recipient Entity
DRAGONFLY RESEARCH LLC
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211597719
Principal investigator 1 TG Therapeutics, Inc. $125.00 06/30/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200185
Principal investigator 1 TG Therapeutics, Inc. $2,500.00 06/01/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200183
Principal investigator 1 Genentech, Inc. $906.00 05/14/2025 Non-covered Recipient Entity
DRAGONFLY RESEARCH LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211598213
Principal investigator 1 Genentech, Inc. $91,707.00 05/09/2025 Non-covered Recipient Entity
DRAGONFLY RESEARCH LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211598205
Principal investigator 1 Genentech, Inc. $8,734.84 04/15/2025 Non-covered Recipient Entity
DRAGONFLY RESEARCH LLC
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211597710
Principal investigator 1 TG Therapeutics, Inc. $11,100.00 03/31/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200179
Principal investigator 1 TG Therapeutics, Inc. $1,250.00 03/27/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200181
Principal investigator 1 TG Therapeutics, Inc. $6,450.00 02/28/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200177
Principal investigator 1 Genentech, Inc. $940.00 02/18/2025 Non-covered Recipient Entity
DRAGONFLY RESEARCH LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211598196
Principal investigator 1 Genentech, Inc. $6,249.00 02/14/2025 Non-covered Recipient Entity
DRAGONFLY RESEARCH LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211598201
Principal investigator 1 TG Therapeutics, Inc. $12,350.00 02/01/2025 Non-covered Recipient Entity
Dragonfly Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200175